HAMAM

Despite tremendous advances in modern imaging technology, both early detection and accurate diagnosis of breast cancer are still unresolved challenges. Today, a variety of imaging modalities and image-guided biopsy procedures exist to identify and characterize morphology and function of suspicious breast tissue. However, a clinically feasible solution for breast imaging, which is both highly sensitive and specific with respect to breast cancer, is still missing. As a consequence, unnecessary biopsies are taken and tumours frequently go undetected until a stage where therapy is costly or unsuccessful.

HAMAM (Highly accurate breast cancer diagnosis through integration of biological knowledge, novel imaging modalities, and modelling) project will tackle this challenge by providing a means to seamlessly integrate the available multi-modal images and the patient information on a single clinical workstation. Based on knowledge gained from a large multi-disciplinary database, populated within the scope of this project, suspicious breast tissue will be characterised and classified.

HAMAM will achieve this by:

  • Building the tools needed to integrate datasets / modalities into a single interface.
  • Providing pre processing / standardization tools that will allow for optimal comparison of disparate data
  • Building spatial correlation information datasets to allow for new similarity and multimodal tissue models. These will be key in the detection and diagnosis of breast cancer
  • Building in adaptability that allows for the integration of other sources of knowledge such as tumour models, genetic data, genotype, phenotype and standardised imaging.

The exact diagnosis of suspicious breast tissue is ambiguous in many cases. HAMAM will resolve this using the statistical knowledge extracted from the large case database. The clinical workstation will suggest additional image modalities that may be captured to optimally resolve these uncertainties. The workstation thus guides the clinician in establishing a patient specific optimal diagnosis. This ultimately leads to a more specific and individual diagnosis.

For further information, please visit:
http://www.hamam-project.eu

Project co-ordinator:
EIBIR gemeinnuetzige GmbH zur Foerderung der. Erforschung der biomedizinischen Bildgebung

Partners:

  • Boca Raton Community Hospital Inc (USA)
  • MeVis Research GmbH (Germany)
  • MeVis Medical Solutions AG (Germany)
  • University College London (United Kingdom)
  • Radboud Universiteit Nijmegen - Stichting Katholieke Universiteit (Netherlands)
  • Charité - Universitätsmedizin Berlin (Germany)
  • The University of Dundee (United Kingdom)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)

Timetable: from 09/2008 - to 08/2011

Total cost: € 4.250.000

EC funding: € 3.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Siemens Healthineers Uses Artificial Int…

Siemens Healthineers introduces Ysio X.pree(1), the world's first intelligent X-ray system with integrated AI for optimizing the daily routine of image acquisition in radiography. To assist radiologists with the subsequent...

Digital Mental Health Interventions Have…

Treating anxiety and depression with digital mental health therapy has a significant and long-term benefit for recovery, new research amongst NHS service users suggests. The research was undertaken by SilverCloud...

Roche Improves Speed and Accuracy of Non…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The...

FDA Permits Marketing of First Game-Base…

The U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only...

Philips Announces Collaboration with Ame…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has once again joined forces with the American Telemedicine Association (ATA) to help further the...

Successful Debut for DMEA sparks

16 - 18 June 2020, Berlin, Germany. DMEA sparks opened, featuring a wide range of topics. Federal Minister of Health Jens Spahn kicked off events. In his interview he focused on...

Brazilian Scientists Develop COVID-19 Ac…

Researchers at São Paulo State University (UNESP) in Araçatuba, Brazil, have developed a computational tool that acts like a "COVID-19 accelerometer," plotting in real time the rate at which growth...

Wearable Injectors and Connected Devices…

7 - 8 October 2020, London, United Kingdom. The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved...

Member States Agree on an Interoperabili…

Member States, with the support of the Commission, have agreed on a set of technical specifications to ensure a safe exchange of information between national contact tracing apps based on...

Siemens Healthineers Offers Flexible Tel…

With its teamplay myCare Companion software, the company is bringing a new and flexible telemedicine solution to the market that enables remote care for patients with chronic diseases. The teamplay...

Andrea Fiumicelli Appointed as a CEO of …

Dedalus Group, leader in Europe and one of the world's leading players in clinical and healthcare information systems supporting clinical professionals and healthcare facilities thanks to a wide portfolio of...

First Virtual DMEA Comes to an End

16 - 18 June 2020, Berlin, Germany. More than 5,000 participants, over 100 Supporters and more than 500 contributions to the programme - these were the final figures after three days...